Prodrome Sciences is proud to announce the commercial launch of Prodrome-PAC – the high-resolution/accurate mass blood test for assessing pancreatic cancer risk. Prodrome-PAC is a simple blood test that requires no advance preparation. The multi-analyte test accurately determines if a person has a pancreatic cancer specific biomarker deficiency. By knowing pancreatic cancer risk, a person can be monitored closely for the disease in order to detect the cancer at an earlier stage when it is easier to treat.
Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States. Over 85% of persons diagnosed with pancreatic cancer die of the disease. Pancreatic cancer is one of the deadliest cancers because there is no screening program and disease symptoms are not observed until the cancer has advanced to a later stage and is very difficult to treat. Prodrome-PAC is a simple, accessible, and accurate blood test that identifies persons with a high risk of pancreatic cancer. Persons who test positive with the Prodrome-PAC test are recommended to seek diagnostic follow-up procedures.
The association between low blood levels of pancreatic cancer specific (PC) biomarkers and an increased risk of pancreatic cancer has been validated in numerous international clinical trials. Over 95% of persons with pancreatic cancer test positive for a PC biomarker deficiency. Due to technical limitations, first generation blood tests used low resolution technology (triple-quadrupole mass spectrometry) and measured only a single pancreatic cancer biomarker (PC-594) to represent the entire family of biomarkers that are known to be decreased in pancreatic cancer patients. Prodrome-PAC is an advanced multi-PC biomarker test which uses high-resolution/accurate mass technology to simultaneously measure multiple important PC biomarkers. Prodrome-PAC incorporates Prodrome Sciences’ advanced multi-analyte technology to accurately assess the overall PC biomarker level in blood. Prodrome Sciences’ multi-analyte technology reduces the risk of false positive and false negative determinations that may occur when only the single PC-594 biomarker is used to assess the family of PC biomarkers in blood.
Dr. Dayan Goodenowe, Prodrome Sciences’ Founder and CEO and the inventor and patent holder of the high-resolution/accurate mass technology originally used to discover the association between pancreatic cancer and low PC biomarkers, explains the new Prodrome Sciences tests: “when my laboratory first discovered the association between PCs and pancreatic cancer it was not viable to launch a commercial multi-analyte high-resolution/accurate mass-based test with the technology available at that time. I am excited to finally be able to unleash the powerful high-resolution/accurate mass technology that had previously been constrained to only research and discovery applications.”